Attached files
| file | filename |
|---|---|
| EX-99.1 - PRESS RELEASE - Aspira Women's Health Inc. | d343316dex991.htm |
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 30, 2012
Vermillion, Inc.
(Exact name of registrant as specified in its charter)
Commission File Number: 001-34810
| Delaware | 33-059-5156 | |
| (State or other jurisdiction of incorporation) |
(IRS Employer Identification No.) |
12117 Bee Caves Road Building Three, Suite 100, Austin, TX 78738
(Address of principal executive offices, including zip code)
512.519.0400
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 8.01 | Other Events. |
On April 30, 2012, Vermillion, Inc. (the “Company”) issued a press release announcing the resolution of four non-contingent contract claims made by Bio-Rad Laboratories, Inc. (“Bio-Rad”) arising from the sale to Bio-Rad of the Company’s protein research tools and collaborative services business in November 13, 2006. In exchange for a final settlement of the non-contingent claims, Bio-Rad will receive $700,000 from an escrow account established by the Company for the sale transaction. The Company will be returned approximately $1,080,000 from the escrow account, with $50,000 remaining in escrow as security for Bio-Rad’s contingent indemnity claim in respect to the parties’ litigation with Molecular Analytical Systems, Inc.
A copy of the Company’s press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
| Item 9.01 | Financial Statements and Exhibits. |
| (d) Exhibit No. | Description | |
| 99.1 | Press Release dated April 30, 2012 | |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Vermillion, Inc. | ||||||
| Date: April 30, 2012 | By: | /s/ Eric Schoen | ||||
| Eric Schoen | ||||||
| Chief Accounting Officer | ||||||
EXHIBIT INDEX
| Exhibit No. |
Description | |
| 99.1 | Press Release dated April 30, 2012 | |